MD Biosciences Webcasts

On-Demand: Preclinical Cell Based Assays: Benefits and Relationship with In Vivo Models

Too many therapeutics continue to fail during middle to late stage development, while pressure to deliver new drugs increases. It is well recognized that the productivity in drug discovery has decreased in the past years despite an increase in R&D spending. In todays economic climate, every effort must be made to shorten this cycle and reduce spending and late stage failures. Cell based assays offer the potential to screen out compound failures earlier in the discovery and development phase, contributing to an increased productivity.

Points Discussed:

• Cost effective High throughput screening: Evaluate a large number of compounds in a single system or screen one compound through a panel of assays prior to moving into in vivo models.
• Relationship between in vitro and in vivo models
• Simplifying the system: following efficacy in an in vivo model, use a well defined in vitro model to determine mode of action.
• Case study for custom assays: by knowing the end goal, assays can be designed to evaluate the pathways involved

On-demand: Collagen Antibody-induced Arthritis: A short, synchronized and rapid rheumatoid arthritis model that can reduce time and expenditure by 85%.

The collagen-induced arthritis model has been the gold standard for determining efficacy for many years. The lengthy model in addition to the variability between animals has caused researchers to seek alternative methods. Using the ArthritiMab antibody cocktail induces arthritis in just 48 hours. Additionally, the disease onset is synchronized between animals and the model can be completed in as little as 7 days.

Points discussed:

• The pathology of collagen antibody-induced arthritis and its acceptance as an alternative to the CIA model.
• The background on the 4 antibodies in the ArthritoMab antibody cocktail and the epitopes they recognize.
• How to best optimize the model to suit your research program whether you have in-house capabilities or need to outsource.